What are the possible side effects of Platinib?

Pralsetinib is a targeted drug mainly used to treat patients with non-small cell lung cancer (NSCLC) and thyroid cancer who have RET gene mutations. As a new type of targeted therapy drug, Platinib helps inhibit the growth and spread of cancer cells by specifically inhibiting the activity of RET tyrosine kinase. However, despite its high efficacy, platinib may also cause some side effects.

Common side effects include hypertension, constipation, fatigue, musculoskeletal pain, and anemia. Patients may experience fatigue and general discomfort when taking platinib because the drug has a certain impact on the body's metabolism. In addition, because platinib affects liver function, some patients may experience increased liver function indicators, such as increased levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), manifesting as jaundice, loss of appetite, nausea and other symptoms.

Another common adverse reaction is leukopenia and thrombocytopenia, which can lead to reduced immunity and the risk of easy bleeding. Routine blood tests are crucial for patients taking platinib, and regular examinations can help detect and manage these potential risks in a timely manner.

In addition, platinib may cause interstitial lung disease (ILD) or pneumonia. These side effects are more serious and include persistent cough, difficulty breathing, and fever. If patients develop these symptoms, they should stop taking the drug immediately and seek medical help.

Other less common but concerning side effects include hyponatremia, hypophosphatemia, hypocalcemia, and hypercreatinine, which may reflect electrolyte imbalances or renal function problems in the patient. The use of Platinib requires regular monitoring of relevant biochemical indicators under the guidance of a doctor to ensure the safety of the medication.

Reference: https://gavreto.com/